Treatment of invasive candidiasis in neutropenic patients: Systematic review of randomized controlled treatment trials

Leukemia and Lymphoma

Volumn 54, Issue 7, 2013, Pages 1479-1487

  Kanji, Jamil N ^a   Laverdière, Michel ^b   Rotstein, Coleman ^c   Walsh, Thomas J ^d   Shah, Prakesh S ^e   Haider, Shariq ^f  

^a UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

^b MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^c TORONTO GENERAL HOSPITAL   (Canada)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e UNIVERSITY OF TORONTO   (Canada)

^f MCMASTER UNIVERSITY   (Canada)

Author keywords

Amphotericin B; Candidiasis; Echinocandin; Invasive; Neutropenia

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIBIOTIC AGENT; CASPOFUNGIN; CREATININE; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; KETOCONAZOLE; MICAFUNGIN; VORICONAZOLE;

CANCER PATIENT; CANDIDEMIA; CENTRAL VENOUS CATHETER; CREATININE BLOOD LEVEL; DRUG DOSE TITRATION; DRUG SAFETY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FOLLOW UP; HUMAN; HYPOKALEMIA; INFUSION RELATED REACTION; INVASIVE CANDIDIASIS; MORTALITY; NEUTROPENIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENSITIVITY ANALYSIS; SIDE EFFECT; SURVIVAL; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; CANDIDIASIS, INVASIVE; ECHINOCANDINS; HUMANS; NEUTROPENIA; ODDS RATIO; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84879397289     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.745073     Document Type: Review

References (51)

1. Wisplinghoff H, Bischoff T, Tallent SM, et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004 ; 39:309-317. (Pubitemid 39050477)
2. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007;20 : 133-163. (Pubitemid 46167771)
3. Laupland KB, Gregson DB, Church DL, et al. Invasive Candida species infections: a 5 year population-based assessment. J Antimicrob Chemother 2005;56:532-537. (Pubitemid 41264132)
4. Hoban DJ, Zhanel GG, Karlowsky JA. In vitro susceptibilities of Candida and Cryptococcus neoformans isolates from blood cultures of neutropenic patients. Antimicrob Agents Chemother 1999;43 : 1463-1464. (Pubitemid 29259344)
5. Messer SA, Jones RN, Fritsche TR. International surveillance of Candida spp. and Aspergillus spp.: report from the SENTRY Antimicrobial Surveillance Program (2003). J Clin Microbiol 2006 ; 44:1782-1787. (Pubitemid 43726269)
6. Laverdiere M, Labbe A C, Restieri C, et al. Susceptibility patterns of Candida species recovered from Canadian intensive care units. J Crit Care 2007;22:245-250. (Pubitemid 47385967)
7. Zaoutis T E, Argon J, Chu J, et al. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis 2005;41 : 1232-1239. (Pubitemid 41532664)
8. Wey SB, Mori M, Pfaller MA, et al. Hospital-acquired candidemia: the attributable mortality and excess length of stay. Arch Intern Med 1988;148:2642-2645. (Pubitemid 19048184)
9. Wilson LS, Reyes CM, Stolpman M, et al. The direct cost and incidence of systemic fungal infections. Value Health 2002;5:26-34. (Pubitemid 34160368)
10. Bedini A, Venturelli C, Mussini C, et al. Epidemiology of candidemia and antifungal susceptibility patterns in an Italian tertiarycare hospital. Clin Microbiol Infect 2006;12:75-80. (Pubitemid 43372243)
11. Gafter-Gvili A, Vidul L, Goldberg E, et al. Treatment of invasive candidal infections: a systematic review and meta-analysis. Mayo Clin Proc 2008;83:1011-1021.
12. Jadad A R, Moore R A, Carroll D, et al. A ssessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1-12. (Pubitemid 26120810)
13. Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, et al. Eff ect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ 2011;343:d4169.
14. Rex JH, Bennett JE, Sugar AM, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N Engl J Med 1994; 331: 1325-1330. (Pubitemid 24347001)
15. Phillips P, Shafran S, Garber G, et al. Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Eur J Clin Microbiol Infect Dis 1997 ; 16:337-345. (Pubitemid 27271820)
16. Rex JH, Pappas PG, Karchmer AW, et al. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis 2003;36:1221-1228. (Pubitemid 36629929)
17. Kullberg BJ, Sobel JD, Ruhnke M, et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 2005;366:1435-1442. (Pubitemid 41483809)
18. Kujath P, Lerch K, Kochendorfer P, et al. Comparative study of the efficacy of fluconazole versus amphotericin B/flucytosine in surgical patients with systemic mycoses. Infection 1993;21:376-382.
19. Abele-Horn M, Kopp A, Sternberg U, et al. A randomized study comparing fluconazole with amphotericin B/5-flucytosine for the treatment of systemic candida infections in intensive care patients. Infection 1996;24:426-432. (Pubitemid 27023090)
20. Driessen M, Ellis JB, Cooper PA, et al. Fluconazole vs. amphotericin B for the treatment of neonatal fungal septicemia: a prospective randomized trial. Pediatr Infect Dis J 1996;15:1107-1112. (Pubitemid 27014703)
21. Mondal RK, Singhi SC, Chakrabarti A, et al. Randomized comparison between fluconazole and itraconazole for the treatment of candidemia in a pediatric intensive care unit: a preliminary study. Pediatr Crit Care Med 2004;5:561-565.
22. Krause DS, Reinhardt J, Vazquez JA, et al. Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia. Antimicrob Agents Chemother 2004;48:2021-2024. (Pubitemid 38691592)
23. Colombo AL, Perfect J, DiNubile M, et al. Global distribution and outcomes for candida species causing invasive candidiasis: results from an international randomized double-blind study of caspofungin versus amphotericin B for the treatment of invasive candidiasis. Eur J Clin Microbiol Infect Dis 2003;22:470-474. (Pubitemid 37100593)
24. Pfaller MA, Diekema DJ, Boyken L, et al. Eff ectiveness of anidulafungin in eradicating candida species in invasive candidiasis. Antimicrob Agents Chemother 2005;49:4795-4797. (Pubitemid 41552623)
25. DiNubile MJ, Lupinacci RJ, Strohmaier KM, et al. Invasive candidiasis treated in the intensive care unit: observations from a randomized clinical trial. J Crit Care 2007; 22: 237-244. (Pubitemid 47380232)
26. Presterl E, Graninger W. Efficacy and safety of fluconazole in the treatment of systemic fungal infections in pediatric patients. multicentre study group. Eur J Clin Microbiol Infect Dis 1994;13:347-351. (Pubitemid 24139815)
27. Nguyen MH, Peacock JE Jr, Tanner DC, et al. Therapeutic approaches in patients with candidemia. Evaluation in a multicenter, prospective, observational study. Arch Intern Med 1995; 155: 2429-2435.
28. Anaissie E J, Vartivarian S E, Abi-Said D, et al. Fluconazole versus amphotericin B in the treatment of hematogenous candidiasis: a matched cohort study. Am J Med 1996;101:170-176. (Pubitemid 26296778)
29. Huttova M, Hartmanova I, Kralinsky K, et al. Candida fungemia in neonates treated with fluconazole: report of forty cases, including eight with meningitis. Pediatr Infect Dis J 1998;17:1012-1015. (Pubitemid 28549422)
30. Juster-Reicher A, Leibovitz E, Linder N, et al. Liposomal amphotericin B (AmBisome) in the treatment of neonatal candidiasis in very low birth weight infants. Infection 2000;28:223-226. (Pubitemid 30601420)
31. Ostrosky-Zeichner L, Oude Lashof AM, Kullberg BJ, Rex JH. Voriconazole salvage treatment of invasive candidiasis. Eur J Clin Microbiol Infect Dis 2003;22:651-655. (Pubitemid 37491617)
32. Ostrosky-Zeichner L, Kontoyiannis D, Raffalli J, et al. International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia. Eur J Clin Microbiol Infect Dis 2005;24:654-661. (Pubitemid 41667052)
33. Fainstein V, Bodey GP, Elting L, Maksymiuk A, Keating M, McCredie KB. Amphotericin B or ketoconazole therapy of fungal infections in neutropenic cancer patients. Antimicrob Agents Chemother 1987;31:11-15. (Pubitemid 17212648)
34. Caillot D, Reny G, Solary E, et al. A controlled trial of the tolerance of amphotericin B infused in dextrose or in Intralipid in patients with haematological malignancies. J Antimicrob Chemother 1994; 33: 603-613. (Pubitemid 24110876)
35. Verweij PE, Donnelly JP, Kullberg BJ, Meis JF, De Pauw BE. Amphotericin B versus amphotericin B plus 5-flucytosine: poor results in the treatment of proven systemic mycoses in neutropenic patients. Infection 1994;22:81-85.
36. Anaissie EJ, Darouiche RO, Abi-Said D, et al. Management of invasive candidal infections: Results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature. Clin Infect Dis 1996;23:964-972. (Pubitemid 26367478)
37. Prentice H G, Hann I M, Herbrecht R, et al. Arandomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol 1997;98:711-718. (Pubitemid 27386554)
38. Leenders AC, Danen S, Jansen RLH, et al. Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections. Br J Haematol 1998;103:205-212. (Pubitemid 28470819)
39. Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. New Engl J Med 1999; 340: 764-771. (Pubitemid 29114295)
40. Wingard JR, White MH, Anaissie E, et al. Arandomized, doubleblind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. Clin Inf Dis 2000;31:1155-1163. (Pubitemid 32295443)
41. Winston D J, Hathorn J W, Schuster M G, et al. A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer. Am J Med 2000;108:282-289. (Pubitemid 30110456)
42. Fleming RV, Kantarjian HM, Husni R, et al. Comparison of amphotericin B lipid complex (ABLC) vs. AmBisome in the treatment of suspected or documented fungal infections in patients with leukemia. Leuk Lymphoma 2001; 40: 511-520. (Pubitemid 32303242)
43. Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002;347:2020-2029. (Pubitemid 35461658)
44. Walsh TJ, Pappas P, Winston DJ, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002; 346: 225-234. (Pubitemid 34438861)
45. Walsh TJ, Teppler H, Donowitz GR, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004;351 : 1391-1402.
46. Kuse ER, Chetchotisakd P, da Cunha CA, et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 2007;369:1519-1527. (Pubitemid 46670281)
47. Pappas PG, Rotstein CM, Betts RF, et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007;45:883-893. (Pubitemid 47580382)
48. Reboli AC, Rotstein C, Pappas PG, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007;356 : 2472-2482. (Pubitemid 46919773)
49. Queiroz-Telles F, Berezin E, Leverger G, et al. Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis. Pediatr Inf Dis J 2008; 27: 820-826.
50. Pappas P G, Rex J H, Sobel J D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009;48:503-535.
51. Eschenauer G, DePestel D D, Carver P L. Comparison of echinocandin antifungals. Ther Clin Risk Manag 2007;3:71-97.